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2Abstract 
Glucagon-like peptide 1 (GLP-1) levels may be reduced in type 2 diabetes but it has 
not been established whether a similar impairment exists in gestational diabetes 
mellitus (GDM). We studied this in a prospective cohort study of pregnant women 
(n=144) during oral glucose tolerance test (OGTT). GLP-1, glucose and insulin were 
sampled at 30-minute intervals during a 2-hour 75g OGTT and indices of insulin 
secretion and sensitivity calculated. In a nested case-control study, women with GDM 
(n=19) had 12% lower total GLP-1 secretion (area under the curve; AUC) compared 
to age, ethnicity and gestational-age matched controls (n=19), selected from within 
the lowest quartile of glucose120min values in our cohort. GDM had lower GLP-1 
response in the first 30 minutes (19% lower GLP-130min and 17% lower AUC0to30min) 
after adjustment for possible confounders. Their glucose levels began to diverge at 30 
minutes of the OGTT with increasing insulin levels, and by 120 minutes, their insulin 
levels were three times higher. In a secondary cohort of 57 women, which included 
‘high-normal’ glucose120min values, low GLP-1 AUC0to30min was independently 
associated with lower indices of insulin secretion and sensitivity. In conclusion, we 
have observed that women with GDM have lower GLP-1 response at 30 minutes of 
an OGTT and hyperglycaemia at 120 minutes despite significant hyperinsulinaemia. 
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3Gestational diabetes mellitus (GDM) is defined as diabetes first recognised during 
pregnancy, and is associated with alarmingly higher risk of type 2 diabetes and 
cardiovascular disease in the post-partum years (1). Around 5 – 30% of pregnancies 
globally are affected by GDM depending on the diagnostic criteria used (2; 3), but its 
pathogenesis has not been fully elucidated.   
  
Glucagon-like peptide-1 (GLP-1) is one of two incretin hormones secreted by the L-
cells of the intestines in response to food, particularly glucose and triacylglycerol (4; 
5). Its primary function is to potentiate glucose-induced insulin secretion by 
pancreatic β-cells and together with glucose-independent insulinotropic polypeptide 
(GIP), accounts for around two-thirds of the insulin response after an oral glucose 
load (6).  
 
The incretin effect, defined as the amplification of insulin secretion with oral 
compared to intravenous glucose, is reduced in type 2 diabetes, which may be due to 
decreased secretion of the incretin hormones or reduced responsiveness of the 
pancreatic β–cells to them (7; 8). Impairments in GLP-1 secretion may actually occur 
early in the disease process as shown in adults and adolescents with insulin resistance 
and obesity (9; 10). In addition, lower GIP levels and hyperglucagonemia have been 
demonstrated in type 2 diabetes, impaired glucose tolerance and obesity (11; 12). 
 
The precise role of GLP-1 in pregnancies affected by GDM is still unclear. A search 
of the medical literature revealed five studies which measured GLP-1 levels in GDM 
(13-17). One showed a non-significant decrease in overall stimulated GLP-1 secretion 
between GDM and controls (13) and two did not show such a difference (14; 16). 
Page 3 of 22 Diabetes
4Two measured only fasting GLP-1 (15; 17). All were retrospective studies, after a 
diagnosis of GDM was made and hence there is a need for prospective, adequately 
powered studies to validate the findings.  
 
The primary aim of our study was to determine if there is a difference in GLP-1 
response (as measured by total area under the curve, AUCtotal) during a 2-hour oral 
glucose tolerance test (OGTT) between GDM and controls at the time of diagnosis. 
Secondary aims were to examine the time-course of GLP-1 during the OGTT and its 
relationship with indices of insulin secretion and sensitivity.  
  
Research Design and Methods 
Study design 
A prospective cohort study, with a nested case-control component, was conducted on 
pregnant women between 2014 and 2016 in two hospitals in the West Midlands, UK. 
The National Institute for Health and Care Excellence (NICE) 2015 selective 
screening criteria was used to screen high-risk women for GDM at 26-28 weeks 
gestation (18). Exclusion criteria were pre-gestational diabetes mellitus (type 1 or 
type 2) and multiple gestation. Informed written consent was obtained from all 
participants. The study was approved by the National Research Ethics Committee 
(South Birmingham). 
 
Blood sampling and laboratory analysis 
On the day of OGTT, participants were studied after a minimum of 10 hours 
overnight fast. Plasma and serum samples were taken 0, 30, 60, 90 and 120 minutes of 
the OGTT. Analysis of serum glucose was done by a hexokinase enzymatic method 
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5and insulin by enzyme linked immunosorbance assay (Abcam human insulin ELISA 
kit, Cambridge, UK). Plasma samples were stored at -80
o
C until the end of the study 
when they were transferred on dry ice to University of Copenhagen for analysis of 
GLP-1. GLP-1 measurements were done by radioimmunoassay as previously 
described (19).  
 
Determination of GDM and control groups 
Women were diagnosed with GDM according to the NICE 2015 criteria: fasting 
plasma glucose (glucose0min) ≥5.6 mmol/l or 2-hour plasma glucose (glucose120min) 
≥7.8 mmol/l (18). The control group for the primary outcome (normal glucose 
tolerance, NGT group) was selected from those in the lowest quartile of glucose120min 
values in the cohort, matched for age, ethnicity and gestational age of OGTT to the 
GDM ‘cases’. For the secondary outcome of assessing the relationship between GLP-
1, insulin and glucose as continuous variables, the analyses were expanded to include 
additional participants who had the highest quartile of glucose120min values among the 
non-GDM (known hereafter as the NGT2 subgroup). 
 
Statistical analysis 
Based on a previous study (13), the primary effect size was determined to be 25% 
lower GLP-1 AUCtotal in women who develop GDM compared to controls. To detect 
this difference with 80% power at 5% significance (2-tailed), the estimated sample 
size was 20 cases. Since the detection rate of GDM in our cohort was around 15%, it 
was planned to recruit 150 women into the study.  
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6AUC for GLP-1 was determined using the trapezoidal method and incremental AUC 
calculated as AUC above baseline. Surrogate markers of indices of insulin secretion 
and sensitivity were used in the absence of hyperglycaemic or hyperinsulinaemic-
euglycaemic clamps, namely HOMA2-B (20) and HOMA-IR (insulin0min x 
glucose0min / 135). Insulin sensitivity was additionally measured using the Insulin 
Sensitivity Index (ISI) Stumvoll (0.226 – 0.0032xBMI – 0.0000645xinsulin120min – 
0.0037xglucose90min) and oral glucose sensitivity index (OGIS) which uses 
glucose0min, glucose90min, glucose120min, insulin90min and insulin120min values as well as 
participants height and weight (21-23). The ISIStumvoll and OGIS correlate more highly 
with the gold-standard clamp studies (r=0.79 and r=0.70 respectively) than HOMA-
IR, because they incorporate late phase glucose and insulin levels from the OGTT 
(21; 23; 24). 
 
Statistical analysis was performed using SPSS version 22.0 (25). Comparison of GLP-
1, glucose and insulin parameters between GDM and controls was done by analysis of 
covariance (ANCOVA) with post-hoc Bonferroni adjustment for multiple 
comparisons. All the analyses included the following co-variates: age, BMI, ethnicity, 
smoking and gestational week of OGTT.  
 
Results 
Characteristics of study population and OGTT results 
One hundred and forty-four women completed the study, of whom 22 developed 
GDM. Three of these women were excluded from the primary analysis because their 
GLP-10min or GLP-1120min values were unavailable (which are required for calculation 
of GLP-1 AUCtotal), giving a total of 19 GDM cases and matched NGT controls 
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7(Figure 1). An additional 17 participants (i.e. the NGT2 subgroup) were included for 
the secondary analyses. The maternal characteristics of the 38 women included in the 
primary analysis and 57 women included in the secondary analysis are presented in 
Table 1 and Supplementary Table 1 respectively.  
 
GLP-1, glucose and insulin profiles: GDM and NGT 
Women with GDM had 12% lower GLP-1 AUCtotal (2034 vs 2321 pmol/l.120min; 
adjusted p=0.046) (Figure 2a) and 19% lower GLP-1 at 30mins (16.0 ± 3.90 vs 19.8 ± 
4.52 pmol/l, adjusted p=0.042) (Figure 3a) compared to NGT. The early phase GLP-1 
response, measured as AUC0to30min, was 17% lower in the former group (446 vs 536 
pmol/l.30min; adjusted p=0.041) (Figure 2b).  
 
The higher glucose levels of GDM were prominent from 30 minutes onwards of the 
OGTT but their insulin levels began to diverge at 90 minutes and peaked at 120 
minutes (Figure 3b-c). 
 
Relationship between GLP-1, glucose and insulin parameters: GDM, NGT and 
NGT2 subgroups 
Secondary analyses to determine the associations between GLP-1, glucose and insulin 
were carried out by including the NGT2 group. This represents a group with 
intermediate glucose values at all time-points, although interestingly their insulin 
levels at 90 and 120 minutes were similar to GDM (Figure 3b-c). These women 
showed higher incremental GLP-1 rise overall and in the first 30 mins of OGTT 
compared to GDM group (incremental AUCtotal: 398±455, 685±455, 427±433 
pmol/l.120min; incremental AUC0to30min: 34±46, 61±56 and 56±62 pmol/l.30min in 
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GDM, NGT2 and NGT respectively, p=0.04 GDM vs NGT2 for incremental AUCtotal, 
Figure 3a). 
 
To investigate the relationship between GLP-1 and glucose and insulin, multiple 
linear regression models were fitted looking at predictors of glucose and insulin at the 
5 time-points in the secondary analysis of the cohort (n=57) (Supplementary Table 2). 
None of the GLP-1 parameters were associated with glucose or insulin levels in the 
first 60 minutes of the OGTT (data not shown). A temporal relationship between 
lower GLP-1 AUC0to30min levels and hyperglycemia was observed. GLP-1 AUC0to30min 
was an independent negative predictor of glucose and insulin at 90 and 120 minutes in 
separate models. However when glucose values were added to the insulin regression 
model, the GLP-1 parameter lost significance.  
 
Indices of insulin secretion and sensitivity 
We next sought to investigate the influence of GLP-1 parameters on OGTT-derived 
indices of insulin sensitivity and secretion in our cohort. Women with GDM had 
lower insulin secretion as determined by HOMA2-B than NGT controls (p<0.001, 
Table 1) as well as significantly lower ISIStumvoll and OGIS values than NGT (p<0.001 
for both) and lower ISIStumvoll than the NGT2 subgroup (0.03 ±0.03 vs 0.06±0.04, 
p=0.036). Combining all the patients (n=57) in multiple linear regression analyses, 
GLP-1 AUC0to30min was an independent positive predictor of insulin secretion as 
measured by HOMA2-B. Similarly, GLP-130min, GLP-1 AUC0to30min and GLP-1 
AUCtotal were also positively associated with OGIS, a marker of insulin sensitivity 
and GLP-130min with ISIStumvoll (Supplementary Table 3). 
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Our study reveals 3 key findings:- 1) Overall GLP-1 response is reduced in women 
with GDM compared to a control group selected from the lowest quartile of 
glucose120min values during an OGTT; 2) Impairment in GLP-1 secretion occurs in the 
first 30 minutes in GDM (as shown by lower GLP-130min and AUC0to30min levels) and 
3) The lower GLP-1 levels at 30 minutes may contribute to impaired glucose 
metabolism in pregnancy, regardless of GDM status.  
  
GLP-1 profile in GDM pregnancy 
Our primary outcome result of 12% lower GLP-1 AUCtotal concentrations in GDM 
pregnancies was statistically significant after adjustment for possible confounders. 
Among other studies which reported AUCtotal for GLP-1 response in GDM, Bonde et 
al (13) found a non-significant decrease of 25% in GDM but used a liquid meal test 
and sampled GLP-1 over 4 hours. Two other studies found no difference in the total 
response of GLP-1 in GDM during a 3-hour 100g and 2-hour 75g OGTT respectively 
(14; 16). The study by Cypryk et al had similar sampling times and GLP-1 assay as 
our study but possible reasons for the variance in their results could be a smaller 
sample size (n=13), and differences in baseline BMI, which was higher in our study 
(14).  
 
Impact of low early phase GLP-1 response 
A novel finding of our study was the lower GLP-1 response in the first 30 minutes of 
the OGTT in GDM pregnancies. Lower GLP-1 and insulin responses at 30 minutes of 
an OGTT has been shown in women with a history of GDM despite normal glucose 
values at 5 years post-partum (26). The authors suggest that this may put them at 
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higher risk of progression to type 2 diabetes. However, this was not replicated in 
another cohort (27). Additionally, GLP-1 impairment in the first 30 minutes has been 
demonstrated in non-pregnant adults with pre-diabetes and type 2 diabetes where it 
was shown to influence β-cell function (9). 
 
We observed a correlation between lower GLP-1 levels at 30 minutes and late phase 
high insulin levels during the OGTT. This negative relationship may seem 
paradoxical since one of the primary functions of GLP-1 is to stimulate insulin 
secretion by pancreatic β-cells. Although early phase GLP-1 levels were predictive of 
late phase hyperinsulinemia in our regression analyses, when glucose values (90 and 
120 minutes) were introduced in the model, this relationship weakened. This suggests 
that the late phase hyperinsulinaemia is driven by hyperglycaemia. Therefore, our 
hypothesis is that the early phase GLP-1 response is critical to ensure that pancreatic 
β-cells produce appropriate amount of insulin to deal with a glucose load in a timely 
manner. 
 
Although BMI has been shown to be negatively associated with GLP-1 in T2D (19), 
there was no correlation between 1
st
 trimester BMI and any of the GLP-1 parameters 
in our cohort, nor was it a significant covariate in the ANCOVA analyses of mean 
GLP-130min, AUCtotal, AUC0to30min between the three subgroups (data not shown). This 
lack of association is likely because women in our selectively screened, high-risk 
cohort were predominantly obese and therefore the effect of BMI on GLP-1 secretion 
may not be apparent. 
 
Strengths and weaknesses 
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This is the largest study, to our knowledge, investigating GLP-1 levels in GDM 
pregnancy using the widely available 75g OGTT. Its significant advantage is that at 
the time of GLP-1 sampling, neither the pregnant women nor the research team knew 
her GDM status, thereby minimising selection bias.  
 
However, there are some important limitations which cannot be ignored. Our findings 
cannot be extrapolated to a diverse population of women with GDM, such as women 
from ethnicities other than White Caucasian, or those with predominantly fasting 
hyperglycaemia (15/19 women in our cohort had isolated post-prandial 
hyperglycemia, likely due to the NICE diagnostic criteria). Secondly, we have not 
analysed GIP and glucagon from this cohort and hence cannot be certain that 
impairments in the related incretin hormones will not contribute to our observations. 
However, two previous studies which have measured GIP during GDM (albeit with 
smaller number of patients) have not noticed any difference in GDM (13; 14). 
Additionally, it has been demonstrated that the insulinotropic effect of GIP, rather 
than its secretion, is impaired in type 2 diabetes (28). Therefore, we do not believe 
that plasma GIP results from OGTT will alter the conclusions. Fourthly, whilst our 
study demonstrated that GLP-1 secretion is lower in the early part of the OGTT in 
women with GDM, we cannot be sure that the trough does not occur before 30 
minutes due to lack of sampling at earlier time points.  
 
In summary, we have shown that GDM is associated with a lower GLP-1 response in 
the first 30 minutes of an OGTT, which may independently contribute to late phase 
hyperglycaemia, hyperinsulinaemia as well as reduced insulin sensitivity.  
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Table 1 - Participant characteristics at baseline and during OGTT 
 
Variables GDM NGT p-value 
Number 19 19   
Gestation at baseline (weeks) 12
+5
 (6
+4
, 15
+5
) 12
+3
 (7
+0
, 16
+3
) NS 
Age (yrs) 29.7 ± 5.3 28.4 ± 4.7 NS 
Baseline weight 99.5 ± 17.9 81.2 ± 16.6 0.003 
Baseline BMI (kg/m2)  37.3 ± 7.5 29.1 ± 5.3 0.001 
Waist circumference (cm) 114.7 ± 14.9 96.0 ± 12.9 <0.001 
Current smokers (%)  4 (21.1) 1 (5.9) NS 
Ethnicity (%) 
  
  
European 17 (89.5) 14 (82.4) NS  
South Asian 2 (10.5) 2 (11.8)   
Afro-Caribbean 0 1 (5.9)   
History of GDM in a previous pregnancy 4 (21) 3 (16) NS 
Family history of diabetes mellitus 8 (42) 10 (53) NS 
Gestation of OGTT (weeks) 26
±6 
(15
+6
, 30
+2
) 26
±6 
(15
+6
, 29
+5
) NS 
Fasting glucose (mmol/l)  5.6 ± 1.03, 5.3 (4.5, 8.5)   4.7 ± 0.27, 4.7 (4.2, 5.1) 0.002 
2 hour glucose (mmol/l)  9.3 ± 1.79, 9.0 (5.4, 12.7)  4.8 ± 0.34, 4.8 (4.1, 5.5) <0.001 
Fasting insulin (pmol/l) 50.0 ± 23.5 67.2 ± 51.2 NS 
2 hour insulin (pmol/l) 490.0 ± 235.3 150.7 ± 124.1 <0.001 
Insulin secretion   
HOMA2-B 72.3 ± 19.4 144.7 ± 53.5 <0.001 
Insulin sensitivity (fasting values)   
HOMA-IR 2.18 ± 1.40 2.33 ± 1.77 NS 
Insulin sensitivity (OGTT values)   
Insulin Sensitivity Index (ISIStumvoll) 0.03 ± 0.03 0.10 ± .019 <0.001 
Oral glucose insulin sensitivity (OGIS) 349.0 ± 81.7 472.3 ± 58.3 <0.001 
 
Table showing characteristics of women with gestational diabetes mellitus (GDM, 
cases) and normal glucose tolerance (NGT, controls) at baseline and during oral 
glucose tolerance test (OGTT). Continuous variables are mean (±SD) or median 
(range) and categorical variables are n (%). T-test was used to compare the 
continuous variables and chi-squared test for categorical variables. .  
NS: non-significant 
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Figure legends 
 
Figure 1 Flow diagram illustrating the selection of gestational diabetes mellitus 
(GDM) cases and normal glucose tolerance (NGT) controls for the primary analysis 
(n=38) and additional subjects for the secondary analyses of the study (n=57). The 
NGT control group includes women selected from the lowest glucose120min quartile, 
matched in age, ethnicity and BMI to the GDM cases. The NGT2 subgroup includes 
additional women who had glucose120min in the highest quartile but below the 
threshold for GDM diagnosis.  
 
Figure 2 Univariate scatter plots of two parameters of GLP-1 response during an oral 
glucose tolerance test (OGTT) in pregnant women diagnosed with gestational 
diabetes mellitus (GDM) and controls with normal glucose tolerance, selected from 
the lowest quartile of glucose120min values (NGT). The parameters are (a) total area 
under the curve (AUCtotal, mean 2034 vs 2321 pmol/l.120min; adjusted p=0.046) and 
(b) area under the curve in the first 30 minutes of the OGTT (AUC0to30min, mean 446 
vs 536 pmol/l.30min; adjusted p=0.041).  
 
 
Figure 3 Line charts of (a) GLP-1, (b) glucose and (c) insulin concentrations during 
oral glucose tolerance test (OGTT) in women diagnosed with gestational diabetes 
(GDM, black circles), controls with normal glucose tolerance, selected from the 
lowest quartile of glucose120min values (NGT, white squares) and controls with normal 
glucose tolerance selected from the highest quartile of glucose120min values (NGT2, 
striped triangles)  . The points represent the mean (±SEM) concentrations of the 
respective parameters measured at 30-minute intervals during a 2-hour 75g OGTT. 
Analysis of covariance was used to compare the means of each parameter between the 
GDM and NGT groups after adjustment for age, BMI, ethnicity and smoking. 
* adjusted p<0.05 
** adjusted p<0.01 
*** adjusted p<0.001  
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Figure 2 Univariate scatter plots of two parameters of GLP-1 response during an oral glucose tolerance test 
(OGTT) in pregnant women diagnosed with gestational diabetes mellitus (GDM) and controls with normal 
glucose tolerance, selected from the lowest quartile of glucose120min values (NGT). The parameters are (a) 
total area under the curve (AUCtotal, mean 2034 vs 2321 pmol/l.120min; adjusted p=0.046) and (b) area 
under the curve in the first 30 minutes of the OGTT (AUC0to30min, mean 446 vs 536 pmol/l.30min; adjusted 
p=0.041).  
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Figure 3 Line charts of (a) GLP-1, (b) glucose and (c) insulin concentrations during oral glucose tolerance 
test (OGTT) in women diagnosed with gestational diabetes (GDM, black circles), controls with normal 
glucose tolerance, selected from the lowest quartile of glucose120min values (NGT, white squares) and 
controls with normal glucose tolerance selected from the highest quartile of glucose120min values (NGT2, 
striped triangles)  . The points represent the mean (±SEM) concentrations of the respective parameters 
measured at 30-minute intervals during a 2-hour 75g OGTT. Analysis of covariance was used to compare 
the means of each parameter between the GDM and NGT groups after adjustment for age, BMI, ethnicity 
and smoking.  
* adjusted p<0.05  
** adjusted p<0.01  
*** adjusted p<0.001  
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Supplemental Table 1 – Baseline characteristics, glucose and insulin results of 
participants included in the secondary analysis (n=57) 
 
Table showing the characteristics of the participants included in the secondary 
analysis, which examined the association between GLP-1, glucose and insulin levels 
as continuous variables. The participants’ data are grouped according to their glucose 
status in the table but the analyses were done on the cohort as a whole.  
 
GDM: gestational diabetes mellitus; NGT: normal glucose tolerance (the women who 
were age-, ethnicity- and gestational-age matched controls for the GDM cases in 
primary analysis, selected from the lowest quartile of glucose values); NGT2: normal 
glucose tolerance 2 (the women in highest quartile for glucose120min but below 
threshold for GDM diagnosis); OGTT: oral glucose tolerance test 
  
Variables GDM NGT NGT2 
Number 21 19 17 
Age (yrs) 29.4 ± 5.2 28.4 ± 4.7 31.9 ± 4.3 
Baseline BMI (kg/m
2
)  38.2 ± 8.0 29.1 ± 5.3 32.7 ± 7.8 
Waist circumference (cm) 116.3 ± 16.2 96.0 ± 12.9 107.1 ± 16.1 
Current smokers (%)  4 (19.0) 1 (5.9) 0 (0) 
Ethnicity (%)       
European 18 (85.7) 14 (82.4) 12 (80.0) 
South Asian 3 (14.3) 2 (11.8) 1 (6.7) 
Afro-Caribbean 0 (0) 1 (5.9) 1 (6.7) 
Other 0 (0) 0 (0) 1 (6.7) 
Gestation of OGTT (weeks) 26
+6
 (15
+6
, 30
+2
) 26
±6 
(15
+6
, 29
+5
) 27
+0
 (24
+0
, 33
+0
) 
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Supplementary Table 2 – Multiple linear regression analyses of the predictors of 
serum glucose and insulin levels during OGTT 
 
 
 Predictors of 
glucose90min 
 
Predictors of 
glucose120min 
 
Predictors of 
insulin90min 
Predictors of 
insulin120min 
Model A 
 
GLP-1 AUC0to30min  
(β: -0.24, p=0.039) 
 
GLP-1 AUC0to30min  
(β: -0.29, p=0.025) 
 
GLP-1 AUC0to30min  
(β: -0.32, p=0.031) 
 
GLP-1 AUC0to30min  
(β: -0.30, p=0.026) 
 
Model B  
 
N/A N/A GLP-1 AUC0to30min  
(β: -0.18, p=0.13) 
 
GLP-1 AUC0to30min  
(β: -0.09, p=0.40) 
 
Table showing the association between GLP-1 AUC0oto30min and glucose and insulin at 
90 and 120 minutes during oral glucose tolerance test (OGTT) in the secondary cohort 
(n=57). The strength of association of GLP-1 AUC0oto30min the in the different models 
is given as the β-coefficient with the corresponding p-value.  
 
Model A: The independent variable is GLP-1 AUC0oto30min and covariates are age, 
BMI, ethnicity, smoking status, gestation and glucose0min (for the insulin regression 
analyses insulin0min is a co-variate instead of glucose0min) 
Model B: As for Model A plus all glucose levels up to the corresponding time-point  
N/A: not applicable 
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Supplementary Table 3 - Multiple linear regression analyses of relationship between 
indices of insulin secretion or sensitivity and GLP parameters 

Variables 
Unadjusted model Adjusted model 
Pearson's r p-value β-coefficient p-value 
Insulin secretion indices
a
 
HOMA2-B         
GLP-130min
b
 - NS - NS 
GLP-1 AUC0to30min 0.33 0.026 0.38 0.004 
GLP-1 AUCtotal - NS - NS 
Insulin sensitivity indices
a
 
HOMA-IR         
GLP-130min
b
 - NS - NS 
GLP-1 AUC0to30min - NS - NS 
GLP-1 AUCtotal - NS - NS 
ISI Stumvoll
c
         
GLP-130min
b
 0.33 0.02 0.31 0.035 
GLP-1 AUC0to30min - NS - NS 
GLP-1 AUCtotal - NS - NS 
OGIS
c 
        
GLP-130min
b
 0.41 0.004 0.41 0.004 
GLP-1 AUC0to30min 0.35 0.016 0.34 0.021 
GLP-1 AUCtotal 0.39 0.006 0.38 0.007 

Table showing the association between GLP-1 parameters and OGTT-derived indices 
of insulin secretion and sensitivity. The strength of association of the respective GLP-
1 parameter is given as the Pearson's r value (unadjusted model) or β-coefficient 
(adjusted model) with the corresponding p-value. Only results with significant p-
values are presented.  
a: Independent variables in the model include age, BMI, ethnicity, smoking status, 
gestation of OGTT and GLP-1 parameter (GLP-130min, GLP-1 AUC0to30mins or GLP-1 
AUCtotal respectively) 
b: As for model 'a' plus GLP-10min 
c: As for models 'a' and 'b' but excluding BMI 
NS: non-significant; AUC: area under the curve; ISI: insulin sensitivity index; OGIS: 
oral glucose sensitivity index; OGTT: oral glucose tolerance test 
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